Clinical Trials Directory

Trials / Conditions / Erdheim-Chester Disease

Erdheim-Chester Disease

15 registered clinical trials studyying Erdheim-Chester Disease — 6 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingDETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Y
NCT07440290
Cancer Research UKPhase 2 / Phase 3
RecruitingDETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Posi
NCT05768178
Cancer Research UKPhase 2 / Phase 3
RecruitingHistiocytic Disorder Follow-up Study
NCT05915208
University of Alabama at Birmingham—
UnknownThe Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (EC
NCT05092815
Shanghai Henlius BiotechPhase 2
RecruitingIn-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
NCT05093335
Memorial Sloan Kettering Cancer CenterEARLY_Phase 1
RecruitingCobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
NCT04079179
Carl AllenPhase 2
UnknownSubtypes and Prognostic Factors in Erdheim-Chester Disease
NCT06317246
Meyer Children's Hospital IRCCSN/A
TerminatedA Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
NCT04198818
Haihe Biopharma Co., Ltd.Phase 1 / Phase 2
UnknownGWAS and EWAS in Patients With Erdheim-Chester Disease
NCT06332183
Augusto Vaglio—
WithdrawnDabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations
NCT03794297
National Cancer Institute (NCI)Phase 2
RecruitingRegistry for Patients With Erdheim-Chester Disease and Other Histiocytoses
NCT03329274
Memorial Sloan Kettering Cancer Center—
CompletedUptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement
NCT02608619
Memorial Sloan Kettering Cancer Center—
UnknownLong-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease
NCT02089724
Groupe Hospitalier Pitie-Salpetriere—
TerminatedPilot Study of Tocilizumab in Patients With Erdheim-Chester Disease
NCT01727206
Ospedale San RaffaelePhase 2
Active Not RecruitingBevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With
NCT01552434
M.D. Anderson Cancer CenterPhase 1